Public Employees Retirement System of Ohio raised its position in Celgene Corporation (NASDAQ:CELG) by 0.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 573,626 shares of the biopharmaceutical company’s stock after buying an additional 4,966 shares during the period. Public Employees Retirement System of Ohio’s holdings in Celgene Corporation were worth $71,376,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. State Street Corp raised its stake in Celgene Corporation by 2.3% in the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock worth $4,040,668,000 after buying an additional 723,844 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Celgene Corporation by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock worth $1,255,309,000 after buying an additional 472,067 shares in the last quarter. American Century Companies Inc. raised its stake in Celgene Corporation by 4.4% in the first quarter. American Century Companies Inc. now owns 6,563,791 shares of the biopharmaceutical company’s stock worth $816,733,000 after buying an additional 276,089 shares in the last quarter. Pioneer Investment Management Inc. raised its stake in Celgene Corporation by 15.7% in the first quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock worth $650,911,000 after buying an additional 710,584 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in Celgene Corporation by 4.3% in the first quarter. Legal & General Group Plc now owns 3,587,623 shares of the biopharmaceutical company’s stock worth $446,406,000 after buying an additional 147,263 shares in the last quarter. 78.34% of the stock is owned by hedge funds and other institutional investors.

Shares of Celgene Corporation (NASDAQ:CELG) traded up 0.18% on Wednesday, reaching $131.60. 794,270 shares of the company were exchanged. The company’s 50 day moving average is $134.03 and its 200 day moving average is $124.75. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $139.00. The firm has a market capitalization of $102.96 billion, a PE ratio of 40.76 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping the consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The company’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.44 earnings per share. Analysts forecast that Celgene Corporation will post $7.32 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.watchlistnews.com/public-employees-retirement-system-of-ohio-has-71-38-million-stake-in-celgene-corporation-celg/1495094.html.

Several brokerages have recently issued reports on CELG. BTIG Research lowered shares of Celgene Corporation from a “buy” rating to a “neutral” rating and boosted their price target for the company from $96.93 to $131.70 in a report on Friday, June 30th. Leerink Swann reissued an “outperform” rating and issued a $160.00 price target (up previously from $150.00) on shares of Celgene Corporation in a report on Friday, July 28th. Argus raised shares of Celgene Corporation from a “hold” rating to a “buy” rating and boosted their price target for the company from $96.93 to $160.00 in a report on Monday, July 31st. Credit Suisse Group set a $148.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a report on Thursday, July 6th. Finally, Cann reissued a “buy” rating on shares of Celgene Corporation in a report on Wednesday, June 7th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $147.00.

In other Celgene Corporation news, insider Rupert Vessey sold 4,785 shares of Celgene Corporation stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the sale, the insider now owns 4,004 shares of the company’s stock, valued at $481,200.72. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Michael D. Casey sold 9,250 shares of Celgene Corporation stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $125.59, for a total transaction of $1,161,707.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 253,761 shares of company stock worth $33,792,445. Insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.